-
Je něco špatně v tomto záznamu ?
Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19)
B. Lakatos, J. Kowalska, S. Antoniak, D. Gokengin, J. Begovac, A. Vassilenko, P. Wasilewski, L. Fleischhans, D. Jilich, R. Matulionyte, K. Kase, A. Papadopoulus, N. Rukhadze, A. Harxhi, S. Hofman, G. Dragovic, M. Vasyliev, A. Verhaz, N. Yancheva,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
NLK
Free Medical Journals
od 1999 do Před 2 roky
Medline Complete (EBSCOhost)
od 1999-10-01 do Před 1 rokem
Wiley Free Content
od 1999 do Před 2 roky
PubMed
34859557
DOI
10.1111/hiv.13214
Knihovny.cz E-zdroje
- MeSH
- adenin terapeutické užití MeSH
- COVID-19 * MeSH
- dospělí MeSH
- emtricitabin terapeutické užití MeSH
- farmakoterapie COVID-19 MeSH
- HIV infekce * farmakoterapie MeSH
- HIV séropozitivita * farmakoterapie MeSH
- inhibitory reverzní transkriptasy MeSH
- látky proti HIV * terapeutické užití MeSH
- lékové interakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- retrospektivní studie MeSH
- SARS-CoV-2 MeSH
- tenofovir škodlivé účinky MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
OBJECTIVES: The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. METHODS: The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. RESULTS: In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36-50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). CONCLUSIONS: In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration.
4th Department Hospital for Infectious Diseases in Warsaw Warsaw Poland
Astar Medical Center Lviv Ukraine
Faculty of Medicine in Plzeň Charles University University Hospital Plzeň Plzeň Czech Republic
Infectious Disease Service University Hospital Center of Tirana Tirana Albania
Infectious Diseases AIDS and Clinical Immunology Center Tbilisi Georgia
School of Medicine University Hospital for Infectious Diseases University of Zagreb Zagreb Croatia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017894
- 003
- CZ-PrNML
- 005
- 20220804134441.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/hiv.13214 $2 doi
- 035 __
- $a (PubMed)34859557
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Lakatos, Botond $u HIV Center, National Institute of Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary $1 https://orcid.org/0000000172767639
- 245 10
- $a Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19) / $c B. Lakatos, J. Kowalska, S. Antoniak, D. Gokengin, J. Begovac, A. Vassilenko, P. Wasilewski, L. Fleischhans, D. Jilich, R. Matulionyte, K. Kase, A. Papadopoulus, N. Rukhadze, A. Harxhi, S. Hofman, G. Dragovic, M. Vasyliev, A. Verhaz, N. Yancheva, C. Oprea, Euroguideliness in Central and Eastern Europe (ECEE) Network Group
- 520 9_
- $a OBJECTIVES: The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. METHODS: The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. RESULTS: In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36-50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). CONCLUSIONS: In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration.
- 650 _2
- $a adenin $x terapeutické užití $7 D000225
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a látky proti HIV $x terapeutické užití $7 D019380
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a emtricitabin $x terapeutické užití $7 D000068679
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 12
- $a HIV séropozitivita $x farmakoterapie $7 D006679
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a inhibitory reverzní transkriptasy $7 D018894
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a tenofovir $x škodlivé účinky $7 D000068698
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kowalska, Justyna $u Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
- 700 1_
- $a Antoniak, Sergii $u Viral Hepatitis and AIDS Department at the Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine
- 700 1_
- $a Gokengin, Deniz $u Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey
- 700 1_
- $a Begovac, Josip $u School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Vassilenko, Anna $u Global Fund Grant Management Department, Republican Scientific and Practical Center for Medical Technologies, Minsk, Belarus
- 700 1_
- $a Wasilewski, Piotr $u 4th Department, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland
- 700 1_
- $a Fleischhans, Lukas $u Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Bulovka, Czech Republic
- 700 1_
- $a Jilich, David $u Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Bulovka, Czech Republic
- 700 1_
- $a Matulionyte, Raimonda $u Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- 700 1_
- $a Kase, Kerstin $u West Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Papadopoulus, Antonios $u Medical School, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece
- 700 1_
- $a Rukhadze, Nino $u Infectious Diseases, AIDS and Clinical Immunology Center, Tbilisi, Georgia
- 700 1_
- $a Harxhi, Arjan $u Infectious Disease Service, University Hospital Center of Tirana, Tirana, Albania
- 700 1_
- $a Hofman, Sam $u Faculty of Medicine in Plzeň, Charles University, University Hospital Plzeň, Plzeň, Czech Republic
- 700 1_
- $a Dragovic, Gordana $u Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Vasyliev, Marta $u Astar Medical Center, Lviv, Ukraine
- 700 1_
- $a Verhaz, Antonija $u Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Republika Srpska, Banja Luka, Bosnia and Herzegovina
- 700 1_
- $a Yancheva, Nina $u Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Sofi, Bulgaria
- 700 1_
- $a Oprea, Cristiana $u Carol Davila University of Medicine and Pharmacy, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania $1 https://orcid.org/0000000195812527
- 710 2_
- $a Euroguideliness in Central and Eastern Europe (ECEE) Network Group
- 773 0_
- $w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 23, č. 6 (2022), s. 693-700
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34859557 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134435 $b ABA008
- 999 __
- $a ok $b bmc $g 1821814 $s 1169137
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 23 $c 6 $d 693-700 $e 20211203 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
- LZP __
- $a Pubmed-20220720
